These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26854747)

  • 41. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
    Jiang X; Liu H; Song Z; Peng X; Ji Y; Yao Q; Geng M; Ai J; Zhang A
    Bioorg Med Chem; 2015 Feb; 23(3):564-78. PubMed ID: 25537530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of a novel series of 4-quinolone JNK inhibitors.
    Gong L; Tan YC; Boice G; Abbot S; McCaleb K; Iyer P; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Lukacs CM; Ursula Kammlott R; Kuglstatter A; Goldstein D
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7381-7. PubMed ID: 23142618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs.
    Ye F; Chen L; Hu L; Xiao T; Yu S; Chen D; Wang Y; Liang G; Liu Z; Wang S
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1556-60. PubMed ID: 25736993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.
    He Y; Duckett D; Chen W; Ling YY; Cameron MD; Lin L; Ruiz CH; Lograsso PV; Kamenecka TM; Koenig M
    Bioorg Med Chem Lett; 2014 Jan; 24(1):161-4. PubMed ID: 24332487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
    Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
    Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
    Blake JF; Gaudino JJ; De Meese J; Mohr P; Chicarelli M; Tian H; Garrey R; Thomas A; Siedem CS; Welch MB; Kolakowski G; Kaus R; Burkard M; Martinson M; Chen H; Dean B; Dudley DA; Gould SE; Pacheco P; Shahidi-Latham S; Wang W; West K; Yin J; Moffat J; Schwarz JB
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2635-9. PubMed ID: 24813737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors.
    Park CH; Lee C; Yang JS; Joe BY; Chun K; Kim H; Kim HY; Kang JS; Lee JI; Kim MH; Han G
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2655-60. PubMed ID: 24813730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
    Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
    Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection of fragments for kinase inhibitor design: decoration is key.
    Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
    J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.